News

Shares of UnitedHealth Group (NYSE: UNH), the nation's largest private medical insurer, were up more than 6.6% as of 11 a.m. ET on Friday after the company reported second-quarter earnings. The heal

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

When looking for stocks that can make one richer, investors often start with names they know. The problem is that the names they know also tend to be the names that everyone knows, and these stocks

Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed nearly 20% so far this year. And that leaves the stock trading a few dollars off its record high. It's not surprising Vertex has advanced. The

Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed nearly 20% so far this year. And that leaves the stock trading a few dollars off its record high. It's not surprising Vertex has advanced. The

Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed nearly 20% so far this year. And that leaves the stock trading a few dollars off its record high. It's not surprising Vertex has advanced. The

Shares of Novavax (NASDAQ: NVAX) lost 28% of their value in the first six months of the year, according to data from S&P Global Market Intelligence, extending a downtrend that began in early 2022

Share of GoodRx Holdings (NASDAQ: GDRX) rose more than 32% for the week, as of Thursday at 2:15 p.m. ET, according to data provided by S&P Global Market Intelligence. The healthcare stock is up more

Amgen (NASDAQ: AMGN) is a global leader in biotechnology, with a market capitalization of over $121 billion. The company has a proven track record of developing breakthrough therapies for

Amgen (NASDAQ: AMGN) is a global leader in biotechnology, with a market capitalization of over $121 billion. The company has a proven track record of developing breakthrough therapies for

Amgen (NASDAQ: AMGN) is a global leader in biotechnology, with a market capitalization of over $121 billion. The company has a proven track record of developing breakthrough therapies for

When you invest in industries that are positioned to capitalize on secular trends, owning wonderful businesses for the long haul is all it takes to build wealth and passive income. As the world's

When you invest in industries that are positioned to capitalize on secular trends, owning wonderful businesses for the long haul is all it takes to build wealth and passive income. As the world's

Investing $100 can be a good amount to get started in stocks, especially if you're using a brokerage that charges low commission fees or none at all. And over time, you can steadily grow your

Investing $100 can be a good amount to get started in stocks, especially if you're using a brokerage that charges low commission fees or none at all. And over time, you can steadily grow your

Investing $100 can be a good amount to get started in stocks, especially if you're using a brokerage that charges low commission fees or none at all. And over time, you can steadily grow your

Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't

Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't

Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't

Make money. That's every investor's goal. How each person chooses to achieve that goal makes the difference in exactly how much money they make and how long it takes to make it.

Some stocks are

The S&P 500 is up 15% this year, and there are many stocks that have been performing much better than that. Shares of Hims & Hers Health (NYSE: HIMS) and Viking Therapeutics (NASDAQ: VKTX) have been

Did you know that if you earned an average of 7% per year, your investment would double in 10 years? That's lower than the S&P 500's long-run average of 10%. Investing in some top growth stocks